Trying to learn how to translate from the human translation examples.
From professional translators, enterprises, web pages and freely available translation repositories.
(%) pacienţi cu răspuns plachetar durabila
durable platelet responsea
Last Update: 2012-04-11
Usage Frequency: 2
Quality:
factorul plachetar 4 nu inhibă lepirudina.
platelet factor 4 does not inhibit lepirudin.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
nr. (%) pacienţi cu răspuns plachetar durabila
no. (%) patients with durable platelet responsea
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
plasmatice, inclusiv factorul plachetar 4 (fp4).
fondaparinux does not bind significantly to other plasma proteins, including platelet factor 4 (pf4).
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
(%) pacienţi cu răspuns plachetar durabil cu doză stabilăe
(%) patients with durable
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
nr. (%) pacienţi cu răspuns plachetar durabil cu doză stabilăe
no. (%) patients with durable platelet response with stable dosee
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
clopidogrelul acţionează prin modificarea ireversibilă a receptorului plachetar pentru adp.
clopidogrel acts by irreversibly modifying the platelet adp receptor.
Last Update: 2012-04-11
Usage Frequency: 2
Quality:
prasugrel 5 mg a dovedit un efect antiagregant plachetar mai mare decât clopidogrel 75 mg.
prasugrel 5 mg provided greater antiplatelet effect than clopidogrel 75 mg.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
pacienţii care necesită produse medicamentoase de urgenţă nu sunt consideraţi ca având un răspuns plachetar durabil.
patients requiring rescue medicinal products were not considered for durable platelet response.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
fondaparinux nu se leagă semnificativ de alte proteine plasmatice, inclusiv factorul plachetar 4 (fp4).
fondaparinux does not bind significantly to other plasma proteins, including platelet factor 4 (pf4).
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
fondaparinux nu se leagă semnificativ de alte proteine plasmatice, inclusiv factorul plachetar 4 (fp4). nu
e significantly to other plasma proteins, including platelet factor 4 (pf4).
Last Update: 2012-04-11
Usage Frequency: 2
Quality:
atunci când bivalirudina este administrată concomitent cu un inhibitor plachetar sau un medicament anticoagulant, parametrii clinici şi biologici ai hemostazei trebuie monitorizaţiatent.
when bivalirudin is combined with a platelet inhibitor or an anti-coagulant medicine, clinical and biological parameters of haemostatsis should be regularly monitored.
Last Update: 2012-04-11
Usage Frequency: 2
Quality:
atunci când bivalirudina este administrată concomitent cu un inhibitor plachetar sau un medicament anticoagulant, parametrii clinici şi biologici ai hemostazei trebuie monitorizaţi atent.
when bivalirudin is combined with a platelet inhibitor or an anti-coagulant medicine, clinical and biological parameters of haemostasis should be regularly monitored.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
ticagrelor nu interacţionează cu situs-ul de legare al adp, ci interacţionează cu receptorul plachetar adp p2y12 pentru împiedicarea transducţiei semnalului.
ticagrelor does not interact with the adp binding site itself, but interacts with platelet p2y12 adp-receptor to prevent signal transduction.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
metabolitul principal al ticagrelor este ar-c124910xx, care este de asemenea activ, conform evaluării in vitro a legării de receptorul plachetar adp p2y12.
the major metabolite of ticagrelor is ar-c124910xx, which is also active as assessed by in vitro binding to the platelet p2y12 adp-receptor.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
ca urmare a variabilităţii interindividuale a răspunsului plachetar, la unii pacienţi numărul de trombocite poate scădea brusc sub 50 x 109/l după scăderea dozei sau întreruperea tratamentului.
due to the interindividual variable platelet response, in some patients platelet count may abruptly fall below 50 x 109/l after dose reduction or treatment discontinuation.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
inhibitorii selectivi ai cox-2 diminuă formarea prostaciclinelor sistemice (şi, posibil şi endoteliale), fără afectarea tromboxanului plachetar.
cox-2 inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
de asemenea, inhibă şi receptorul factorului de creştere derivat plachetar (pdgf) şi receptorul factorului de creştere fibroblastic (fgfr3).
it also inhibits the platelet derived growth factor (pdgf) receptor and the fibroblast growth factor receptor (fgfr3).
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
de asemenea, imatinibul inhibă receptorii tirozin kinazici ai factorului de creştere plachetar (pdgf), pdgf-r şi inhibă evenimentele celulare mediate de pdgf.
imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (pdgf), pdgf-r, and inhibits pdgf-mediated cellular events.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
inhibitorii selectivi ai cox-2 inhibă formarea prostaciclinei periferice (şi, de aceea, posibil şi a prostaciclinei endoteliale), fără afectarea tromboxanului plachetar.
cox-2 selective inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.
Last Update: 2017-04-26
Usage Frequency: 3
Quality: